Healthtech funding in H2 2020
European Healthtech startup funding raised during H2 2020.
In H2 2020, 305 European Healthtech companies closed 315 funding rounds and raised €3.7B in equity funding (excluding debt and grants), up 84.4% versus H2 2019. Debt rounds added €65M. UK led by capital raised, and Novo Holdings was the most active investor. Data as of 20 Nov 2026.
Equity funding
€3.7B
+84.4% vs H2 2019 · excl. debt & grants · +€65M debt
Funding rounds
315
+76.0% vs H2 2019
Companies
305
Top country
UK
Rank among sectors
#3
9.5% of sector funding
Debt financing
€65M
1.8% of total
Top-10 round share
24.4%
of disclosed capital
Rounds ≥ €100M
3
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H2 2020 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €858M | 60 |
| Aug | €365M | 40 |
| Sep | €865M | 64 |
| Oct | €776M | 60 |
| Nov | €545M | 51 |
| Dec | €322M | 40 |
Top countries
by € raisedHealthtech — top countries by capital, H2 2020 — interactive chart.
Data table
| Healthtech — top countries by capital, H2 2020 | |
|---|---|
| UK | €722M |
| Israel | €666M |
| Switzerland | €582M |
| France | €380M |
| Sweden | €263M |
| Germany | €218M |
| Spain | €205M |
| Netherlands | €198M |
Stage mix
by € raisedHealthtech — stage mix, H2 2020 — interactive chart.
Data table
| Healthtech — stage mix, H2 2020 | |
|---|---|
| Other | €1.2B |
| Series C | €816M |
| Series A | €523M |
| Series B | €470M |
| Series D+ | €398M |
| Seed | €165M |
| Debt | €65M |
| Early VC | €47M |
| Growth/Late | €42M |
| Crowdfunding | €8.6M |
| Pre-Seed | €7.7M |
| Grant | €7.4M |
Exits & M&A
12 Acquisition · 2 IPO15 exits · €1.4B disclosed.
| MYR GmbH | Acquisition | Oct 2020 | €1.1B |
| Nanox Imaging | IPO | Aug 2020 | €140M |
| Fiagon | Acquisition | Sep 2020 | €60M |
| Oni | Acquisition | Nov 2020 | €40M |
Top deals
largest disclosed rounds in H2 2020| Company | Stage | Date | Amount |
|---|---|---|---|
| Kry | Series C | Jul 2020 | €140M |
| Freeline Therapeutics | Series C | Jul 2020 | €107M |
| Atai Life Sciences | Series C | Nov 2020 | €105M |
| Sophia Genetics | Series D+ | Oct 2020 | €94M |
| Vectivbio | Other | Oct 2020 | €94M |
| Neogene Therapeutics | Other | Sep 2020 | €93M |
| Freeline Therapeutics | Series C | Jul 2020 | €71M |
| Lava Therapeutics | Series C | Sep 2020 | €70M |
| Melio | Series C | Sep 2020 | €68M |
| Pharvaris | Series C | Nov 2020 | €67M |
| Sight Diagnostics | Series D+ | Jul 2020 | €61M |
| Sight | Series D+ | Aug 2020 | €60M |
| Achilles Therapeutics | Other | Nov 2020 | €59M |
| Imcheck Therapeutics | Other | Sep 2020 | €54M |
| F2G | Other | Aug 2020 | €52M |
Top investors
most active in H2 2020, by deal count- Novo Holdings5 deals
- Bpifrance4 deals
- Wellington Partners4 deals
- Fountain Healthcare Partners3 deals
- Horizon 20203 deals
- Invivo Capital Partners3 deals
- Kurma Partners3 deals
- Parkwalk Advisors3 deals
- 4FO Ventures2 deals
- Adara Ventures2 deals